Molecular Glue Therapeutics Patent Landscape Analysis Report 2026 Edition

Molecular Glue Therapeutics Market Size, Growth Trends, and Industry Outlook

Molecular glue therapeutics are small molecules that induce or stabilise an interaction between two proteins that would not otherwise associate, allowing a ligase to tag a disease-driving protein for destruction or altering its function. The class entered clinical practice through thalidomide and its analogues, whose mechanism was only explained after cereblon was identified as their target in 2010. Demand remains concentrated in haematological malignancies, where oral dosing, long treatment durations and established reimbursement have supported sustained use. The pipeline is now widening toward transcription factors, translation factors and kinases that conventional inhibitors cannot engage, and toward immune-mediated disease. Commercial dynamics are shaped by the gap between ageing marketed products and a still maturing generation of successors.

Market growth is driven by next-generation cereblon modulators such as iberdomide and mezigdomide, which are in late-stage clinical development to extend responses in relapsed and refractory multiple myeloma after lenalidomide resistance and to carry revenue as older products lose protection. Lenalidomide, the largest legacy product, faces unrestricted generic entry in the United States from 2026, which shifts the revenue base toward successors and explains why expansion is moderate despite a busy pipeline. Multiple myeloma accounts for more than 170,000 new cases worldwide each year, and a growing share of patients receive combination regimens built around a cereblon modulator, which sustains per-patient drug exposure.

Generic entry is the main near-term headwind. Lenalidomide has been the best-selling product in the class for years, so even partial price erosion removes a large amount of revenue; the effect is gradual because volume entry was staged under settlement agreements, which gave successors time to reach patients. Pomalidomide faces a comparable transition on a smaller revenue base, so the legacy decline is spread across several years rather than concentrated in one. Against this, each new indication matters: a glue degrader approved in an earlier line of myeloma therapy or in lymphoma adds treated patient-years that older products never reached. Combinations with bispecific antibodies lengthen treatment duration, and early work in lupus extends the addressable population beyond cancer.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Molecular Glue Therapeutics Patent Filing Trends and Innovation Activity

Filing intensity in molecular glue therapeutics has risen steadily since the clinical success of cereblon modulators was matched by structural insight into how glues remodel ligase surfaces. Large pharmaceutical groups have added internal programmes and paid for access to specialist discovery platforms, and each partnership tends to be followed by a new wave of composition-of-matter filings on scaffolds, degrons and substrate lists. Specialist biotechnology companies, many funded through venture rounds and public listings between 2020 and 2022, file early and broadly because patents are their principal balance sheet asset. Academic groups contribute filings on ligase biology and screening methods, though their share is smaller than that of industry.

The analysed set contains more than 5,200 patent families, grouped around six technology clusters: cereblon modulating compounds and next-generation degraders; glues engaging DCAF15, DCAF16 and other substrate receptors; degraders of GSPT1 and zinc finger transcription factors; immunophilin based glues such as rapamycin and tacrolimus analogues; screening and proteomics for rational glue discovery; and oral formulation and combination regimens with bispecific antibodies. Filings peaked between 2020 and 2024, when new family publications ran well above earlier years, led by cereblon compounds and by DCAF-directed chemistry. Cereblon related families remain the largest single group by count.

Rising treated populations in myeloma and lymphoma, together with growing evidence in immunology, have pushed companies to protect successor chemistry and new ligase and target pairs, so patent expansion follows demand that legacy products can no longer meet on their own.

Scope of the Molecular Glue Therapeutics Patent Landscape Analysis Report

The scope covers global patent filings in molecular glue therapeutics across the United States, China, Europe, Japan, South Korea and India, together with applications filed through the World Intellectual Property Organization. Market coverage spans legacy cereblon modulating drugs, clinical-stage glue degraders and preclinical programmes disclosed in published applications. Granted patents, pending applications and published families are all counted, with legal status used to separate enforceable rights from lapsed filings. The market view runs from 2025 to 2035 and links patent activity to revenue from marketed products and to the expected timing of late-stage readouts.

Technology scope is organised by E3 ligase class (cereblon, DCAF family substrate receptors, other Cullin-RING ligase receptors and non-degrader immunophilin glues), by target class (zinc finger transcription factors, GSPT1 and translation factors, kinases and signaling proteins, cell cycle regulators and other previously undruggable targets) and by therapeutic area (multiple myeloma, lymphomas and leukemias, solid tumors, immunology and inflammation, and neurodegenerative and other disorders). Small molecules that induce or stabilise protein-protein interactions are included. Heterobifunctional degraders are treated only as an adjacent technology boundary.

Entities covered include established pharmaceutical groups with legacy cereblon franchises, specialist biotechnology companies built on glue discovery platforms, Japanese and European oncology developers, and start-ups spun out of university laboratories. Academic and clinical institutions, such as cancer research centres and myeloma treatment networks, appear as applicants and as sites for early clinical work. Contract research organisations and screening technology providers are included where they hold filings on assay or proteomics methods.

Global Molecular Glue Therapeutics Patent Landscape Analysis

Molecular Glue Therapeutics Patent Filing Trend Analysis

Patent publications in molecular glue therapeutics have moved from a narrow base centred on thalidomide analogues to a broad, multi-company portfolio over the past decade. Early filings covered cereblon binding scaffolds; later waves added DCAF15 sulfonamides, GSPT1 degraders and screening methods, so the number of distinct chemical series has grown faster than the number of applicants. Grants lag filings by two to four years, and the more than 10 patents granted in 2025 reflect applications made in the early 2020s.

Annual filing growth between 2020 and 2024 is estimated at approximately 12 percent, driven by venture-backed platform companies, new partnerships with large pharmaceutical groups and sustained interest in cereblon successors. A smaller share of the increase comes from China, where domestic developers have raised filings on cereblon modulators and glue screening. Activity on immunophilin based glues has been steadier, in line with an older and narrower field.

Leading Companies and Assignee Analysis in the Molecular Glue Therapeutics Patent Landscape

Geographic Analysis of Molecular Glue Therapeutics Patent Activity

The report assesses patent activity across major jurisdictions, including:

• United States
• Europe
• China
• Japan
• South Korea
• India
• International and WIPO filings

The United States leads filings, supported by the concentration of cereblon pioneers and venture-funded discovery platforms in Massachusetts and California. China ranks second by volume, with domestic biotechnology companies and universities filing on cereblon modulators and screening methods, while Europe is anchored by Swiss, German and British applicants. South Korea and India contribute smaller but growing numbers, largely from academic groups and firms working on lenalidomide process and formulation claims. WIPO filings under the Patent Cooperation Treaty remain the usual route for companies seeking staged entry across several markets.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Molecular Glue Therapeutics Technology Segmentation and Innovation Areas

Technology activity in molecular glue therapeutics is concentrated in five segments:

• Cereblon modulating compounds and next-generation degraders
• Glues engaging DCAF family substrate receptors
• GSPT1 and zinc finger transcription factor degraders
• Immunophilin based glues and analogues
• Rational discovery, screening and proteomics

Cereblon modulating compounds lead patent activity because the target is clinically validated, structurally well characterised and tied to the largest marketed revenue base. Companies file on successor scaffolds to renew exclusivity as lenalidomide and pomalidomide lose protection, and each new substrate identified for cereblon generates further claims. DCAF family glues are the fastest growing segment from a smaller base, with interest in DCAF15 and DCAF16 chemistry rising as developers look beyond cereblon to reduce dependence on a single ligase.

Competitive Landscape and Emerging Trends in the Molecular Glue Therapeutics Market

Competition spans three groups: established pharmaceutical owners of cereblon franchises, platform biotechnology companies, and large developers that partner for access. The cereblon incumbents defend a mature estate while advancing successors in myeloma and lymphoma. Platform companies such as Monte Rosa Therapeutics and C4 Therapeutics compete on discovery speed and on the breadth of ligase and substrate pairs they can claim. Partnerships between large pharmaceutical groups and these specialists have become a common route, usually with milestone structures that tie value to clinical progress. New entrants, including firms from China and Japan, are filing on DCAF family glues and screening technologies, which extends the field beyond the original cereblon group.

Companies are focusing on:

• Next-generation cereblon modulators
• Glues recruiting DCAF family receptors
• GSPT1 degraders for leukemia and solid tumors
• Proteomics-driven glue discovery
• Oral dosing and formulation improvements
• Combinations with bispecific antibodies
• Immunology and neurodegeneration indications

Several themes are emerging. Monovalent degraders of IKZF1 and IKZF3 aim to deepen responses beyond lenalidomide, while GSPT1 degraders have been tested in acute myeloid leukaemia and MYC-driven solid tumours. Systematic mapping of ligase and substrate pairs, supported by chemoproteomics and structural biology, is turning serendipitous glue discovery into a design problem. Applications in lupus and other autoimmune disease are growing as Ikaros and Aiolos degradation is explored outside oncology. Claims on degron sequences and substrate selectivity profiles are also appearing alongside conventional compound claims, which will make freedom-to-operate reviews more detailed.

Strategic Insights from the Molecular Glue Therapeutics Patent Landscape

The molecular glue therapeutics patent landscape combines a mature cereblon estate with a fast-growing set of filings on new ligases, new substrates and discovery methods. Expiring exclusivity on legacy products, active partnerships and the first late-stage data on successors make the current period unusually informative for decisions on freedom to operate and portfolio gaps. Claims increasingly cover degron sequences, ligase binding motifs and combination use rather than composition alone, so reading the landscape means tracking several claim types at once.

The molecular glue therapeutics patent landscape provides actionable intelligence for:

• Intellectual property strategy for glue scaffolds
• R&D prioritisation across ligase and target pairs
• Competitive benchmarking of glue portfolios
• Technology scouting for novel ligase receptors
• Licensing evaluation of cereblon successors
• Partnership assessment with platform companies
• Investment analysis of glue developers
• Market entry planning in new indications
• Portfolio expansion beyond cereblon

Research Methodology for the Molecular Glue Therapeutics Patent Landscape Analysis

Patent research covered the United States Patent and Trademark Office, the European Patent Office, the China National Intellectual Property Administration, the Japan Patent Office, the Korean Intellectual Property Office, the Indian patent office and WIPO PATENTSCOPE, supplemented by Espacenet and public legal status records. Search strategies combined Cooperative Patent Classification codes for cereblon and ubiquitin ligase chemistry with keywords for named modulators, ligase receptors and substrate proteins. Results were consolidated into patent families so that each invention is counted once across jurisdictions.

Records were screened for relevance to small molecules that induce or stabilise protein-protein interactions, and heterobifunctional degraders, antibody based degraders and unrelated immunosuppressant uses were removed. Remaining families were classified by E3 ligase class, target class, therapeutic area, assignee, jurisdiction and technology cluster. Assignee names were harmonised across subsidiaries and acquisitions so that portfolio sizes reflect corporate ownership as published.

Market analysis support draws on public regulatory approvals, clinical trial registries, company filings and published sales of marketed products to align patent activity with commercial progress. Patent counts are treated as indicators of innovation direction rather than commercial success, and estimates such as growth rates and shares are rounded and approximate. Findings were reviewed for internal consistency before inclusion in the report.

Related Reports

Multiple Myeloma Pipeline Analysis

Molecular Diagnostics Market

Molecular Diagnostics Patent Landscape